Tina Kurent

Ljubljana, Slovenia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?

Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?

Journal: European journal of gastroenterology & hepatology

Published: April 16, 2024

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.

Journal: Medicina (Kaunas, Lithuania)

Published: January 08, 2024

Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis.

Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis.

Journal: European journal of gastroenterology & hepatology

Published: March 26, 2023

Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.

Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.

Journal: Journal of Crohn's & colitis

Published: July 27, 2022

Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model.

Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model.

Journal: Pharmaceutics

Published: September 06, 2021

Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.

Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.

Journal: European journal of gastroenterology & hepatology

Published: August 17, 2021

The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease.

The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease.

Journal: Biochemia medica

Published: September 09, 2020

Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.

Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.

Journal: European journal of gastroenterology & hepatology

Published: August 18, 2020

Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.

Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 03, 2019

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.

Journal: United European gastroenterology journal

Published: December 11, 2018

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

Journal: Alimentary pharmacology & therapeutics

Published: September 08, 2018

Success and safety of high infliximab trough levels in inflammatory bowel disease.

Success and safety of high infliximab trough levels in inflammatory bowel disease.

Journal: Scandinavian journal of gastroenterology

Published: July 11, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026